Latest news with #Nona
Yahoo
23-05-2025
- Business
- Yahoo
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. MesoC2, originally developed using Nona's proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC). Poster Presentation at the 2025 ASCO Annual MeetingTitle: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumorsAbstract Number: TPS3163Poster Board Number: 475aSession Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor BiologySession Date and Time: 02 June 2025; 1:30 PM-4:30 PM (CDT) Key Highlights from the Presentation: MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8). MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys. The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts. "We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology." Pfizer's presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at (NCT06466187). About MesoC2 (HBM9033/PF-08052666) MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option. About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences
Yahoo
23-05-2025
- Business
- Yahoo
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2, an MSLN-Targeting ADC, at the 2025 ASCO Annual Meeting
CAMBRIDGE, Mass., May 23, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced that its collaborator, Pfizer, will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. MesoC2, originally developed using Nona's proprietary Harbour Mice® and integrated ADC platforms, was licensed to Pfizer in December 2023 under a global rights agreement. Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumors, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC). Poster Presentation at the 2025 ASCO Annual MeetingTitle: A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumorsAbstract Number: TPS3163Poster Board Number: 475aSession Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor BiologySession Date and Time: 02 June 2025; 1:30 PM-4:30 PM (CDT) Key Highlights from the Presentation: MesoC2 is an ADC composed of a human IgG1 anti-MSLN monoclonal antibody conjugated to a cleavable tripeptide linker carrying a topoisomerase 1 inhibitor (TOP1i) payload (average drug-to-antibody ratio of 8). MesoC2 has shown potent antitumor efficacy in in vitro assays and xenograft models and an acceptable safety profile in cynomolgus monkeys. The Phase 1 trial (NCT06466187) will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy per RECIST v1.1 criteria of MesoC2 in up to 365 patients across dose escalation, optimization, and expansion cohorts. "We are excited to see Pfizer advancing MesoC2 into clinical development rapidly, highlighting the potential of Nona's Harbour Mice® and integrated ADC platforms to deliver innovative cancer therapies," said Dr. Jingsong Wang, Chairman of Nona Biosciences. "The initiation of this Phase 1 trial marks a significant milestone in our collaboration and underscores our shared commitment to addressing unmet needs in oncology." Pfizer's presentation at the 2025 ASCO Annual Meeting will provide further insights into the trial design. Additional details on the study can be found at (NCT06466187). About MesoC2 (HBM9033/PF-08052666) MesoC2 (HBM9033/PF-08052666) is an ADC drug that targets human MSLN, a tumor-associated antigen (TAA) upregulated in various solid tumors. The fully human monoclonal antibody (mAb) in MesoC2 is derived from the Harbour Mice® platform and possesses well-tuned properties, exhibiting reduced binding to soluble MSLN while maintaining strong binding and internalization to membrane-bound MSLN. The unique design of the mAb was created to enhance potency in various preclinical tumor models with differing MSLN expression levels, positioning MesoC2 as a potential globally best-in-class therapeutic option. About Nona Biosciences Nona Biosciences is a global biotechnology company committed to cutting edge technology innovation and providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research. The integrated antibody and antibody-related discovery services with multiple modalities range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs. For more information, please visit: View original content to download multimedia: SOURCE Nona Biosciences Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Rakyat Post
07-05-2025
- Business
- Rakyat Post
Pastry Entrepreneur Sues Younger Sisters And Brother RM1.5mil In Ultimate Sibling Rivalry
Subscribe to our FREE It's pretty normal for siblings to get into a tiff every now and then. It could be over a small thing such as who gets the front seat of the car when going on a car ride with mom and dad, or something a bit more serious such as reading another sibling's diary. But, what happens when there's bad blood over a business that cost probably hundreds of thousands in the making? That's what happened recently between four siblings, whose quarrel has escalated into a million-ringgit lawsuit. A pastry business owner claims she and her siblings were sued by their eldest sister Engku Putri Nadira Arshad, a co-owner of pastry outlet Eclairis, claimed on Instagram yesterday (6 May) that The Ordinary Baker, owned by her eldest sister Engku Putri Sharizad Arshad, is suing Eclairis for RM1.5 million. 'One of us made a decision that left the other three of us with no choice but to walk away. We didn't take a single cent. We just left. Quietly. 'And now we're being sued for RM1.5 million. It still hurts to say that out loud,' the caption wrote. The four siblings started The Ordinary Baker together in 2020 amidst the Covid-19 pandemic, and business was good. Throughout 2021, they operated out of their home, baking cream puffs and all sorts of pastries with whatever they could fit in their house. Come November 2021, they opened their first store in Setia Alam, which quickly went viral and was even featured on national television (RTM). Later in 2023, they expanded by opening another store in Shah Alam and went viral again, with local television channel TV3 featuring them on a segment of 'Nona'. The eldest sister claims she paid to set up the business, and settled her siblings' debts Meanwhile, according to a She claimed that the last of her investment into The Ordinary Baker was meant for a wedding cake business she wanted to set up for herself. 'I sacrificed my dream so they could have theirs. None of them contributed a single cent. But that's ok, after all OB was set up to help my family who at the time had no jobs,' she wrote in the caption. The entrepreneur then said the initial plan was to give the store's shares to her siblings but claimed that two of them were blacklisted. She then decided to delay putting their names on the company's shares until she settles their debts, which she claimed she did. She claimed that her siblings had accrued debts of up to RM100,000 which included money owed to TEKUN, a governmental small-to-medium enterprise (SME) development organisation, an education loan, loan sharks, and to her husband. 'Why is it important to clear your names before entering the company? For OB to grow, it needs financing, and financial institutions will do a background check – this is the reason their names are not there. I decided to go solo so it's easier for me to manage risks,' she said. The three siblings resigned after their eldest sister refused to open a third outlet In the same Facebook post, Sharizad accused her siblings of executing a coordinated attack on her by resigning with a 24-hour notice from the company on 1 November, 2024. She claimed to have no prior knowledge about it and ran the company single-handedly, hoping her siblings would return to work. However, they set up a new company two weeks after they left. The new business, Eclairis, allegedly used the same branding and recipes as The Ordinary Baker. According to her, this happened after she refused to open a third outlet just months after opening their first and second ones, explaining that the second store has not even reached its target return on investment (ROI). Amidst the chaos, she also highlighted the welfare of The Ordinary Baker's staff, who face risks such as retrenchment and paycuts, if she were forced to close one or all the outlets. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.
New Straits Times
22-04-2025
- Entertainment
- New Straits Times
#SHOWBIZ: Edika Yusof: Divorce proceedings are a 'birthday present' for me
KUALA LUMPUR: XX-Ray actor Edika Yusof said that while he was shocked to learn that his wife Nor Hidayah had filed for divorce without consulting him, it was her "birthday present" for him. The 58-year-old actor said that even if his marriage were to end after 22 years, he felt relieved and accepted his fate. "If this makes her happy, there is nothing I can do," he said in a TikTok video for the women's magazine Nona recently. Edika said that he had "done his best" as a husband for two decades for his wheelchair-bound wife. "April 22 is my birthday and the court case takes place tomorrow. I gues that's my birthday gift from her," he said. Last month, Nor Hidayah filed for divorce at the Federal Territories Syariah Court. Edika and Nor Hidayah tied the knot in 2003, and have two childen. She also has a son from a previous marriage.
Yahoo
16-04-2025
- Health
- Yahoo
This fast-growing health and nutrition chain is opening a Bayshore and West Bend location
A health food chain that's added several suburban locations in the last five years is going to add two more. Nona Nutrition, a nutrition and wellness store and eatery, will be opening a Bayshore and West Bend location later this year. Owner Seth Knapp said Nona Nutrition was launched in 2018 "from a place of passion." He said it is "all things health and nutrition." Its first store opened in Pewaukee (at 1350 Capitol Drive) in 2019. Since then, Nona has opened locations in Delafield (525 Main St.), Elm Grove (13320 Watertown Plank Road) and Mequon (1400 W. Mequon Road). Knapp said the Bayshore location should open by the end of the summer or early fall and the West Bend location should open in the fall. Knapp said the Bayshore location will be at 5800 N. Bayshore Drive in Glendale, across from the Nike Well Collective. The West Bend location will be at the Sendik's Plaza, 280 N. 18th Ave., next to Planet Fitness. Nona Nutrition has açaí smoothie bowls with many different add-ons including protein enhancers. Other menu items are a Paradise Bowl (with a base of Brazilian açaí, dragon fruit, strawberries, and whey protein) and the Ultimate Green Bowl (with a base of Brazilian açaí, Organifi green juice superfood blend, blueberries, strawberries and whey protein). Both include grain-free coconut cashew granola, banana slices, peanut butter, chia seeds, almond slices, toasted coconut flakes and raw honey toppings. Nona Nutrition offers more than 10 different smoothies. Options include lavender lemon blueberry (lavender, lemon omega, blueberries, banana, raw honey, superfood creamer and whey protein); pink dragon (dragon fruit, pineapple, banana, coconut cream, raw honey and banana whey protein) and green dream (spinach, banana, pineapple, mango nectar, coconut cream, raw honey and banana whey protein). Nona Nutrition offers traditional coffee drinks such as lattes and cappuccinos, as well as specialty coffees including a maple lavender latte and a vanilla honeycomb latte. For more information, visit or Cathy Kozlowicz can be reached at 262-361-9132 or Follow her on Twitter at @kozlowicz_cathy. More: Indoor pickleball, a bakery and a gift shop are now open in Menomonee Falls and West Bend More: McBrats and Teenie Beanies: West Bend woman reflects on 44 years at McDonald's This article originally appeared on Milwaukee Journal Sentinel: Nona Nutrition to open locations at Bayshore and in West Bend in 2025
